Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion type Assertion NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_head.
- NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion description "[It aroused considerable interest well beyond the hematologic field during the last five years since APL has two unique features i) the remission of the disease obtained with all-trans retinoic acid (ATRA) treatment ii) the presence in APL blasts of an abnormal protein, the promyelocytic myeloid leukemia/retinoic acid receptor (PML/RAR alpha) protein.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_provenance.
- NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion evidence source_evidence_literature NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_provenance.
- NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion SIO_000772 8535190 NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_provenance.
- NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion wasDerivedFrom befree-2016 NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_provenance.
- NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_assertion wasGeneratedBy ECO_0000203 NP1344576.RAbzLyHMMuVKu50QoJCSJoyNJ4rTEropPf5hL3JQfyrNY130_provenance.